Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.78
CYTX's Cash to Debt is ranked lower than
83% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. CYTX: 0.78 )
Ranked among companies with meaningful Cash to Debt only.
CYTX' s Cash to Debt Range Over the Past 10 Years
Min: 0.17  Med: 4.32 Max: No Debt
Current: 0.78
Equity to Asset 0.32
CYTX's Equity to Asset is ranked lower than
85% of the 703 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. CYTX: 0.32 )
Ranked among companies with meaningful Equity to Asset only.
CYTX' s Equity to Asset Range Over the Past 10 Years
Min: -1.1  Med: 0.15 Max: 0.94
Current: 0.32
-1.1
0.94
F-Score: 5
Z-Score: -12.42
M-Score: -2.11
WACC vs ROIC
23.98%
-430.42%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -131.10
CYTX's Operating margin (%) is ranked lower than
57% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -65.33 vs. CYTX: -131.10 )
Ranked among companies with meaningful Operating margin (%) only.
CYTX' s Operating margin (%) Range Over the Past 10 Years
Min: -3958.33  Med: -272.90 Max: -131.11
Current: -131.1
-3958.33
-131.11
Net-margin (%) -160.75
CYTX's Net-margin (%) is ranked lower than
60% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -63.93 vs. CYTX: -160.75 )
Ranked among companies with meaningful Net-margin (%) only.
CYTX' s Net-margin (%) Range Over the Past 10 Years
Min: -3620.2  Med: -289.87 Max: -157.61
Current: -160.75
-3620.2
-157.61
ROA (%) -46.30
CYTX's ROA (%) is ranked lower than
67% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: -26.04 vs. CYTX: -46.30 )
Ranked among companies with meaningful ROA (%) only.
CYTX' s ROA (%) Range Over the Past 10 Years
Min: -127.5  Med: -80.16 Max: -49.06
Current: -46.3
-127.5
-49.06
ROC (Joel Greenblatt) (%) -632.25
CYTX's ROC (Joel Greenblatt) (%) is ranked lower than
57% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. CYTX: -632.25 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CYTX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1697.26  Med: -1092.50 Max: -608.21
Current: -632.25
-1697.26
-608.21
Revenue Growth (3Y)(%) -30.50
CYTX's Revenue Growth (3Y)(%) is ranked lower than
78% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. CYTX: -30.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CYTX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -14.00 Max: 87.6
Current: -30.5
0
87.6
EBITDA Growth (3Y)(%) -40.40
CYTX's EBITDA Growth (3Y)(%) is ranked lower than
88% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. CYTX: -40.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CYTX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -40.4  Med: -16.20 Max: 37.5
Current: -40.4
-40.4
37.5
EPS Growth (3Y)(%) -36.90
CYTX's EPS Growth (3Y)(%) is ranked lower than
83% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. CYTX: -36.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CYTX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -41.5  Med: -13.60 Max: 102.9
Current: -36.9
-41.5
102.9
» CYTX's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-05-11)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

CYTX Guru Trades in Q3 2014

Jim Simons 475,131 sh (New)
Paul Tudor Jones Sold Out
» More
Q4 2014

CYTX Guru Trades in Q4 2014

Jim Simons Sold Out
» More
Q2 2015

CYTX Guru Trades in Q2 2015

George Soros 22,400 sh (New)
» More
Q3 2015

CYTX Guru Trades in Q3 2015

George Soros Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CYTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 0.97
CYTX's Forward P/E is ranked higher than
99% of the 85 Companies
in the Global Biotechnology industry.

( Industry Median: 17.79 vs. CYTX: 0.97 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 4.76
CYTX's P/B is ranked lower than
66% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. CYTX: 4.76 )
Ranked among companies with meaningful P/B only.
CYTX' s P/B Range Over the Past 10 Years
Min: 2.06  Med: 32.03 Max: 792
Current: 4.76
2.06
792
P/S 3.52
CYTX's P/S is ranked higher than
76% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 10.84 vs. CYTX: 3.52 )
Ranked among companies with meaningful P/S only.
CYTX' s P/S Range Over the Past 10 Years
Min: 1.53  Med: 12.12 Max: 42.53
Current: 3.52
1.53
42.53
Current Ratio 2.52
CYTX's Current Ratio is ranked lower than
69% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. CYTX: 2.52 )
Ranked among companies with meaningful Current Ratio only.
CYTX' s Current Ratio Range Over the Past 10 Years
Min: 1.36  Med: 2.50 Max: 32.68
Current: 2.52
1.36
32.68
Quick Ratio 2.01
CYTX's Quick Ratio is ranked lower than
72% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. CYTX: 2.01 )
Ranked among companies with meaningful Quick Ratio only.
CYTX' s Quick Ratio Range Over the Past 10 Years
Min: 1.06  Med: 2.28 Max: 31.14
Current: 2.01
1.06
31.14
Days Inventory 513.82
CYTX's Days Inventory is ranked lower than
96% of the 441 Companies
in the Global Biotechnology industry.

( Industry Median: 121.91 vs. CYTX: 513.82 )
Ranked among companies with meaningful Days Inventory only.
CYTX' s Days Inventory Range Over the Past 10 Years
Min: 47.13  Med: 287.45 Max: 529.06
Current: 513.82
47.13
529.06
Days Sales Outstanding 32.93
CYTX's Days Sales Outstanding is ranked higher than
76% of the 602 Companies
in the Global Biotechnology industry.

( Industry Median: 65.97 vs. CYTX: 32.93 )
Ranked among companies with meaningful Days Sales Outstanding only.
CYTX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.15  Med: 64.69 Max: 124.26
Current: 32.93
4.15
124.26
Days Payable 115.56
CYTX's Days Payable is ranked higher than
69% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 64.47 vs. CYTX: 115.56 )
Ranked among companies with meaningful Days Payable only.
CYTX' s Days Payable Range Over the Past 10 Years
Min: 25.87  Med: 116.71 Max: 414.3
Current: 115.56
25.87
414.3

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.29
CYTX's Price/Median PS Value is ranked higher than
89% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 0.95 vs. CYTX: 0.29 )
Ranked among companies with meaningful Price/Median PS Value only.
CYTX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.18  Med: 1.12 Max: 1.78
Current: 0.29
0.18
1.78
Price/Graham Number 2.31
CYTX's Price/Graham Number is ranked lower than
57% of the 293 Companies
in the Global Biotechnology industry.

( Industry Median: 2.48 vs. CYTX: 2.31 )
Ranked among companies with meaningful Price/Graham Number only.
CYTX' s Price/Graham Number Range Over the Past 10 Years
Min: 0.34  Med: 1.48 Max: 3.53
Current: 2.31
0.34
3.53
Earnings Yield (Greenblatt) (%) -24.86
CYTX's Earnings Yield (Greenblatt) (%) is ranked lower than
73% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. CYTX: -24.86 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CYTX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -91.21  Med: 0.00 Max: 0
Current: -24.86
-91.21
0

More Statistics

Revenue(Mil) $12
EPS $ -0.19
Beta3.43
Short Percentage of Float2.51%
52-Week Range $0.13 - 0.95
Shares Outstanding(Mil)195.19

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 35 113 185
EPS($) -0.03 0.33 0.67
EPS without NRI($) -0.03 0.33 0.67

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:CHMA, LSE:MTPH, TSX:QLT, NAS:PIRS, XKLS:7178, ASX:ACR » details
Traded in other countries:XMPA.Germany,
Cytori Therapeutics Inc was incorporated in the State of Delaware in May 1997. The Company is engaged in the development of novel treatments for cardiovascular disease and soft tissue injuries and burns. Its core product is the Celution System, which extracts the naturally occurring ADRCs from a patient's own fat tissue and is CE Marked for a range of soft tissue procedures, including breast reconstruction. The company has completed three clinical trials using the Celution System for breast reconstruction, pipeline applications acute myocardial infarction, and chronic myocardial ischemia. It is involved in the European ADVANCE trial for acute myocardial infarction; and the U.S. trial for chronic myocardial ischemia. The company also sells StemSource cell banking line, including cell and tissue banking lines, as well as the Puregraft System that optimizes the fat graft preparation process. Its therapeutic areas comprises of cardiovascular disease, specifically refractory heart failure due to chronic myocardial ischemia, and the treatment of thermal burns. Its customers in Japan consist of researchers at academic hospitals and clinics. It also has a network of distributors who offer Celution Systems, instrumentation and consumables and Puregraft System to surgeons and hospitals throughout Europe. Celution Systems are or will be subject to stringent government regulation in the United States by the FDA under the Federal Food, Drug and Cosmetic Act.
» More Articles for NAS:CYTX

Headlines

Articles On GuruFocus.com
Wall Street’s Best and Worst Calls of the First Quarter 2015 May 07 2015 
5-year lows: Fuel Systems Solutions Inc, Dawson Geophysical Co, Forest Oil Corp, and Cytori Therapeu Sep 08 2014 
Weekly CFO Buys Highlight: SSP, BMTI, POL, ANAC, CYTX Mar 26 2012 
Weekly CFO Buys Highlight: SSP, HPOL, CYTX, AGYS, VRX, TPI Mar 19 2012 
Cytori Therapeutics Inc Reports Operating Results (10-Q) Aug 09 2010 
Cytori Therapeutics Inc (CYTX) CFO Mark E Saad buys 6,000 Shares May 21 2010 
Cytori Therapeutics Inc Reports Operating Results (10-Q) Aug 10 2009 
Cytori Therapeutics Inc (CYTX) CEO Christopher J Calhoun buys 6,600 Shares May 20 2009 
Cytori Therapeutics Inc (CYTX) CEO Christopher J Calhoun buys 3,250 Shares May 19 2009 
Cytori Therapeutics Inc (CYTX) CEO Christopher J Calhoun buys 7,000 Shares May 18 2009 

More From Other Websites
Cytori to Webcast First Quarter Financial Results on May 10 Apr 29 2016
Cytori to Webcast First Quarter Financial Results on May 10 Apr 29 2016
Cytori Announces Timing for Full Enrollment in U.S. Phase III Scleroderma Trial Apr 27 2016
Cytori Announces Timing for Full Enrollment in U.S. Phase III Scleroderma Trial Apr 27 2016
ETF’s with exposure to Cytori Therapeutics, Inc. : April 26, 2016 Apr 26 2016
Cytori Therapeutics (CYTX) Shows Strength: Stock Up 13.2% Apr 19 2016
Top Penny Stocks: Four Trending Small Cap Stocks That Require Your Attention on April 18th 2016 Apr 18 2016
Cytori Strengthens Global Patent Portfolio Apr 18 2016
Cytori Strengthens Global Patent Portfolio Apr 18 2016
Cytori Strengthens Global Patent Portfolio Apr 18 2016
Cytori Therapeutics to Present Preliminary Safety and Efficacy Preclinical Data at the 2016 American... Apr 14 2016
Cytori Therapeutics to Present Preliminary Safety and Efficacy Preclinical Data at the 2016 American... Apr 14 2016
New Strong Buy Stocks for April 8th Apr 08 2016
ETF’s with exposure to Cytori Therapeutics, Inc. : April 4, 2016 Apr 04 2016
Put These on Your Stocks to Watch List for Thursday 3/24/2016, If You Choose Mar 24 2016
Cytori Update on Its U.S. Phase III Scleroderma Trial Mar 24 2016
Cytori Update on Its U.S. Phase III Scleroderma Trial Mar 24 2016
Cytori Granted SME Status by European Medicines Agency Mar 23 2016
Cytori Granted SME Status by European Medicines Agency Mar 23 2016
ETF’s with exposure to Cytori Therapeutics, Inc. : March 22, 2016 Mar 22 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK